AstraZeneca plc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Direxion Daily FTSE China Bull 3x Shares trades at $29.03. The key difference: AstraZeneca plc pays a 2.01% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals.
| AZN | YINN | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $56.62 |
52-Week Low | $147.06 | $21.45 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
YINN, a leveraged ETF tracking Chinese stocks, trades at $29.01, down 10.19% amid broad bearish technical signals. Key support lies at $29, with RSI at 24.06 indicating potential oversold conditions. Recent news highlights China's AI investments and export strength, but U.S.-China tech tensions and regulatory scrutiny persist.
The outlook remains clouded by geopolitical risks and leveraged ETF decay, though oversold conditions may offer tactical opportunities. Risks include amplified volatility and policy shifts, requiring cautious positioning given the fund's structure and macro sensitivities.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →